

### Main characteristics of the Initial, Expansion, Overall and Sibling Cohort Participants

Characteristic <sup>#</sup>		Original cohort <sup>1</sup> (n=14,348)		Expansion cohort <sup>2</sup> (n=11,387)		Overall cohort <sup>3</sup> (n=25,735)		Sibling cohort (n=5045)	
		N	(%)	N	(%)	N	(%)	N	(%)
Sex	Male	7701	(53.7)	6061	(53.4)	13762	(53.6)	2404	(47.7)
	Female	6647	(46.3)	5326	(46.6)	11973	(46.4)	2641	(52.3)
Race	White	13026	(90.8)	9248	(80.9)	22274	(85.7)	4554	(90.3)
	Black	711	(5.0)	999	(8.3)	1710	(6.7)	151	(3.0)
	American Indian / Alaska Native	89	(0.6)	66	(0.6)	155	(0.6)	23	(0.5)
	Asian or Pacific Islander	167	(1.2)	250	(2.4)	417	(1.8)	53	(1.1)
	Other	225	(1.6)	819	(7.7)	1044	(4.8)	92	(1.8)
	Unknown	130	(0.9)	5	(0.0)	135	(0.5)	172	(3.4)
Ethnicity	Hispanic	752	(5.2)	1313	(12.3)	2065	(8.9)	216	(4.3)
	Non-Hispanic	12949	(90.2)	10056	(87.6)	23005	(88.9)	4629	(91.8)
	Unknown	647	(4.5)	18	(0.1)	665	(2.2)	200	(4.0)
Age at cancer diagnosis	0-4 yrs	5746	(40.0)	4484	(45.2)	10230	(42.7)	-	
	5-9 yrs	3199	(22.3)	2595	(25.0)	5794	(23.7)	-	
	10-14 yrs	2913	(20.3)	2544	(18.1)	5457	(19.1)	-	
	15-20 yrs	2490	(17.4)	1762	(11.7)	4252	(14.4)	-	
Primary diagnosis	ALL	4327	(30.2)	2319	(41.4)	6646	(36.0)	-	
	AML	356	(2.5)	574	(3.7)	930	(3.1)	-	
	Other leukemia	145	(1.0)	187	(1.2)	332	(1.1)	-	
	Astrocytoma	1182	(8.2)	1513	(9.8)	2695	(9.0)	-	
	Medulloblastoma/PNET	380	(2.6)	660	(4.3)	1040	(3.5)	-	
	Other CNS malignancy	311	(2.2)	452	(2.9)	763	(2.6)	-	
	Hodgkin lymphoma	1923	(13.4)	1188	(7.7)	3111	(10.4)	-	
	Non-Hodgkin lymphoma	1081	(7.5)	1038	(6.7)	2119	(7.1)	-	
	Kidney tumors	1254	(8.7)	1025	(6.6)	2279	(7.6)	-	
	Neuroblastoma	955	(6.7)	1000	(6.5)	1955	(6.6)	-	
	Soft tissue sarcoma	1245	(8.7)	516	(3.3)	1761	(5.9)	-	
	Ewing sarcoma	404	(2.8)	337	(2.2)	741	(2.5)	-	
	Osteosarcoma	733	(5.1)	526	(3.4)	1259	(4.2)	-	
	Other bone malignancy	52	(0.4)	51	(0.3)	103	(0.3)	-	
Vital status at baseline	Alive	13173	(91.8)	10744	(94.9)	23918	(93.4)	5033	(99.7)
	Dead	1175	(8.2)	642	(5.1)	1817	(6.6)	12	(0.2)
Treatment	Chemo + RT + Surgery	5039	(35.1)	3391	(24.1)	8430	(29.4)	-	
	Chemo + RT	1676	(11.7)	657	(8.3)	2333	(9.9)	-	

Characteristic <sup>#</sup>		Original cohort <sup>1</sup> (n=14,348)		Expansion cohort <sup>2</sup> (n=11,387)		Overall cohort <sup>3</sup> (n=25,735)		Sibling cohort (n=5045)	
		N	(%)	N	(%)	N	(%)	N	(%)
	Chemo + Surgery	2239	(15.6)	3277	(25.5)	5516	(20.7)	-	
	Chemo only	904	(6.3 )	1726	(26.2)	2630	(16.6)	-	
	RT + Surgery	1504	(10.5)	505	(3.3 )	2009	(6.7 )	-	
	RT only	42	(0.3 )	26	(0.2 )	68	(0.2 )	-	
	Surgery only	915	(6.4 )	1253	(8.1 )	2168	(7.3 )	-	
	No treatment	29	(0.2 )	48	(0.3 )	77	(0.3 )	-	
	Med. Rec. Not Available	2000	(13.9)	504	(4.1 )	2504	(8.8 )	-	

<sup>1</sup>20,674 eligible, <sup>2</sup>17,347 eligible, <sup>3</sup>38,021 eligible

<sup>#</sup>Percentages for individual characteristics calculated on total number of participants providing information for those characteristics

<sup>\*</sup>Percentages weighted to reflect modified sampling of ALL survivors in expansion cohort

RT = radiotherapy

**Treatment Exposure During First 5 Years After Primary Cancer by Cancer Diagnosis:  
Expansion Cohort Participants with Complete Abstraction of Medical Records (N=9747)<sup>1</sup>**

Agent		Participants		Leukemia		CNS		HD		NHL		Kidney		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Total		9747	100.0	2439	100.0	2369	100.0	1052	100.0	880	100.0	879	100.0	873	100.0	445	100.0	810	100.0
Any radiation	Yes	4175	43.2	791	32.6	1210	51.7	805	77.5	164	18.8	421	48.2	240	27.7	327	73.8	217	27.1
	No	5487	56.8	1636	67.4	1129	48.3	234	22.5	710	81.2	452	51.8	625	72.3	116	26.2	585	72.9
	Pending	85	.	12	.	30	.	13	.	6	.	6	.	8	.	2	.	8	.
Max dose to brain <sup>1</sup>	None	5764	61.2	1687	71.5	1165	52.9	300	28.9	720	83.8	495	56.8	649	76.2	146	33.3	602	75.2
	1-19.9 Gy <sup>2</sup>	2357	25.0	542	23.0	44	2.0	738	71.0	121	14.1	374	42.9	177	20.8	183	41.8	178	22.2
	20-29.9 Gy	157	1.7	112	4.7	4	0.2	1	0.1	8	0.9	1	0.1	18	2.1	11	2.5	2	0.2
	30-49.9 Gy	151	1.6	19	0.8	59	2.7	0	0.0	9	1.0	1	0.1	5	0.6	46	10.5	12	1.5
	>=50 Gy	995	10.6	0	0.0	932	42.3	0	0.0	1	0.1	0	0.0	3	0.4	52	11.9	7	0.9
	Pending	323	.	79	.	165	.	13	.	21	.	8	.	21	.	7	.	9	.
Max dose to chest	None	5840	61.4	1700	71.6	1279	54.8	263	26.3	721	83.9	486	56.4	648	76.1	145	33.1	598	75.0
	1-19.9 Gy <sup>2</sup>	2355	24.7	668	28.1	529	22.7	100	10.0	122	14.2	355	41.2	165	19.4	272	62.1	144	18.1
	20-29.9 Gy	655	6.9	6	0.3	175	7.5	423	42.3	4	0.5	13	1.5	30	3.5	1	0.2	3	0.4
	>=30 Gy	666	7.0	1	0.0	350	15.0	215	21.5	12	1.4	7	0.8	9	1.1	20	4.6	52	6.5
	Pending	231	.	64	.	36	.	51	.	21	.	18	.	21	.	7	.	13	.
Neck	Yes	1821	18.9	329	13.6	539	23.1	723	69.6	64	7.3	11	1.3	84	9.7	44	9.9	27	3.4
	No	7833	81.1	2097	86.4	1797	76.9	316	30.4	809	92.7	860	98.7	781	90.3	399	90.1	774	96.6
	Pending	93	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	9	.
Spine	Yes	1068	11.1	334	13.8	585	25.0	8	0.8	42	4.8	0	0.0	81	9.4	7	1.6	11	1.4
	No	8586	88.9	2092	86.2	1751	75.0	1031	99.2	831	95.2	871	100.0	784	90.6	436	98.4	790	98.6
	Pending	93	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	9	.
Abdomen	Yes	1907	19.8	327	13.5	545	23.3	308	29.6	54	6.2	379	43.5	196	22.7	53	12.0	45	5.6
	No	7746	80.2	2099	86.5	1791	76.7	731	70.4	819	93.8	492	56.5	669	77.3	390	88.0	755	94.4
	Pending	94	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	10	.
Pelvis	Yes	1625	16.8	324	13.4	534	22.9	176	16.9	55	6.3	238	27.3	120	13.9	102	23.0	76	9.5
	No	8029	83.2	2102	86.6	1802	77.1	863	83.1	818	93.7	633	72.7	745	86.1	341	77.0	725	90.5
	Pending	93	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	9	.
Limb	Yes	553	5.7	251	10.3	4	0.2	59	5.7	45	5.2	2	0.2	89	10.3	29	6.5	74	9.2
	No	9101	94.3	2175	89.7	2332	99.8	980	94.3	828	94.8	869	99.8	776	89.7	414	93.5	727	90.8
	Pending	93	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	9	.
TBI	Yes	375	3.9	249	10.3	2	0.1	4	0.4	34	3.9	0	0.0	74	8.6	1	0.2	11	1.4

	No	9279	96.1	2177	89.7	2334	99.9	1035	99.6	839	96.1	871	100.0	791	91.4	442	99.8	790	98.6
	Pending	93	.	13	.	33	.	13	.	7	.	8	.	8	.	2	.	9	.
Any chemotherapy	Yes	7966	82.7	2416	99.7	1087	47.2	959	92.6	874	99.9	860	97.9	546	63.1	442	99.8	782	96.9
	No	1665	17.3	7	0.3	1217	52.8	77	7.4	1	0.1	18	2.1	319	36.9	1	0.2	25	3.1
	Pending	116	.	16	.	65	.	16	.	5	.	1	.	8	.	2	.	3	.
Alkylating agents (CED, mg/m2) <sup>1</sup>	None	4073	44.5	913	39.7	1513	68.2	277	28.5	58	7.0	761	87.5	331	41.8	90	21.6	130	17.2
	>0 - <4000	1271	13.9	699	30.4	73	3.3	77	7.9	210	25.3	18	2.1	108	13.6	15	3.6	71	9.4
	>=4000 - <8000	1466	16.0	284	12.4	111	5.0	431	44.3	330	39.7	23	2.6	182	23.0	14	3.4	91	12.0
	>=8000 - <12000	1051	11.5	311	13.5	224	10.1	117	12.0	161	19.4	29	3.3	45	5.7	38	9.1	126	16.7
	>=12000 - <16000	464	5.1	63	2.7	139	6.3	41	4.2	28	3.4	25	2.9	53	6.7	39	9.4	76	10.1
	>=16000 - <20000	245	2.7	16	0.7	79	3.6	13	1.3	21	2.5	2	0.2	31	3.9	29	7.0	54	7.1
	>=20000	586	6.4	13	0.6	79	3.6	17	1.7	23	2.8	12	1.4	42	5.3	192	46.0	208	27.5
	Unknown	591	.	140	.	151	.	79	.	49	.	9	.	81	.	28	.	54	.
Anthracycline dose (mg/m2) <sup>1</sup>	None	3992	42.6	340	14.5	2279	99.1	149	14.8	103	12.2	422	48.8	386	46.7	278	64.5	35	4.5
	>0 - <100	926	9.9	599	25.6	0	0.0	56	5.6	83	9.8	62	7.2	94	11.4	11	2.6	21	2.7
	>=100 - <250	2696	28.7	908	38.8	7	0.3	646	64.3	433	51.3	278	32.2	287	34.7	37	8.6	100	13.0
	>=250 - <400	1349	14.4	402	17.2	12	0.5	146	14.5	191	22.6	97	11.2	50	6.1	73	16.9	378	49.0
	>=400	415	4.4	89	3.8	2	0.1	7	0.7	34	4.0	5	0.6	9	1.1	32	7.4	237	30.7
	Unknown	369	.	101	.	69	.	48	.	36	.	15	.	47	.	14	.	39	.

<sup>1</sup> Unknown doses are excluded from percentage calculations, <sup>2</sup> Includes scatter doses of radiation

**Treatment Exposure During First 5 Years After Primary Cancer by Cancer Diagnosis:  
Expansion Cohort Participants with Complete Abstraction of Medical Records (N=9747)**

Agent	Participants		Leukemia		CNS		HD		NHL		Kidney (Wilms)		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
5-Azacytidine	109	1.1	107	4.4	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ARA-G	4	0.0	2	0.1	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Bleomycin	795	8.3	0	0.0	3	0.1	683	65.8	18	2.1	0	0.0	0	0.0	7	1.6	84	10.4
Busulfan	180	1.9	159	6.6	4	0.2	6	0.6	1	0.1	3	0.3	0	0.0	2	0.5	5	0.6
Carboplatin	781	8.1	5	0.2	364	15.7	16	1.5	38	4.3	52	5.9	218	24.9	18	4.1	70	8.7
Carmustine (BCNU)	111	1.2	3	0.1	29	1.3	35	3.4	41	4.7	0	0.0	2	0.2	0	0.0	1	0.1
Chlorambucil	5	0.1	0	0.0	0	0.0	5	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cisplatin	1401	14.5	2	0.1	548	23.8	31	3.0	42	4.8	0	0.0	381	43.5	34	7.7	363	44.8
Cyclophosphamide-All Routes	4723	48.3	1542	62.3	436	18.9	478	45.4	823	92.7	92	10.5	552	61.6	340	74.2	460	55.8
Cyclophosphamide-IV/IM	4469	46.4	1474	60.8	420	18.2	461	44.5	809	92.5	89	10.1	463	53.5	325	73.4	428	53.0
Cyclophosphamide-PO	173	1.8	12	0.5	8	0.3	0	0.0	1	0.1	1	0.1	129	14.9	0	0.0	22	2.7
Cytarabine	3198	32.5	2358	91.0	67	2.9	70	6.8	666	74.2	3	0.3	7	0.8	17	3.8	10	1.2
Dacarbazine (DTIC)	382	4.0	0	0.0	23	1.0	308	29.7	0	0.0	0	0.0	35	4.0	3	0.7	13	1.6
Dactinomycin	1529	15.8	12	0.5	49	2.1	4	0.4	5	0.6	834	92.2	6	0.7	388	86.0	231	28.5
Daunorubicin	1936	20.0	1690	68.8	1	0.0	6	0.6	228	25.9	2	0.2	4	0.5	2	0.5	3	0.4
Dexamethasone	1942	20.0	1182	48.0	200	8.7	110	10.6	178	20.3	21	2.4	51	5.9	46	10.3	154	18.7
Doxorubicin	4204	43.4	761	31.3	21	0.9	897	85.6	631	71.6	461	52.2	488	55.6	165	37.2	780	95.7
Epirubicin	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0
Etoposide (VP-16)-All Routes	2964	30.4	1071	43.6	365	15.7	188	18.0	279	31.8	106	12.0	447	50.1	167	37.2	341	41.3
Etoposide (VP-16)-IV/IM	2811	29.2	1028	42.4	329	14.3	179	17.3	275	31.4	101	11.5	418	48.3	160	36.1	321	39.8
Etoposide (VP-16)-PO	69	0.7	21	0.9	30	1.3	2	0.2	1	0.1	0	0.0	7	0.8	1	0.2	7	0.9
Fludarabine phosphate	67	0.7	51	2.1	2	0.1	3	0.3	5	0.6	0	0.0	2	0.2	1	0.2	3	0.4
Fluorouracil (5-FU)	7	0.1	2	0.1	1	0.0	1	0.1	1	0.1	0	0.0	1	0.1	1	0.2	0	0.0
Gemcitabine	17	0.2	0	0.0	0	0.0	4	0.4	0	0.0	1	0.1	1	0.1	2	0.5	9	1.1
Gemtuzimab (Mylotarg)	6	0.1	3	0.1	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	0	0.0	1	0.1
Gleevec	15	0.2	8	0.3	1	0.0	0	0.0	0	0.0	0	0.0	1	0.1	3	0.7	2	0.2
Hydroxyurea	178	1.8	77	3.2	63	2.7	0	0.0	33	3.8	1	0.1	4	0.5	0	0.0	0	0.0
Idarubicin	180	1.9	172	7.1	4	0.2	1	0.1	3	0.3	0	0.0	0	0.0	0	0.0	0	0.0
Ifosfamide	1107	11.5	33	1.4	61	2.6	27	2.6	74	8.5	43	4.9	111	12.8	220	49.0	538	64.8
Irinotecan	43	0.4	3	0.1	11	0.5	0	0.0	0	0.0	2	0.2	16	1.8	6	1.4	5	0.6
L-Asparaginase	2161	22.2	1865	74.5	2	0.1	12	1.2	275	31.3	0	0.0	3	0.3	1	0.2	3	0.4
Lomustine (CCNU)	382	4.0	0	0.0	364	15.8	17	1.6	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Mechlorethamine (N. Mustard)	340	3.5	1	0.0	17	0.7	309	29.8	3	0.3	0	0.0	10	1.2	0	0.0	0	0.0
Melphalan-All Routes	158	1.6	10	0.4	7	0.3	3	0.3	2	0.2	4	0.5	94	10.9	17	3.8	21	2.6

Melphalan-IV/IM	151	1.6	9	0.4	6	0.3	3	0.3	1	0.1	4	0.5	90	10.4	17	3.8	21	2.6
Melphalan-PO	2	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	0	0.0	0	0.0
Mercaptopurine (6-MP)	1884	19.4	1663	66.7	4	0.2	2	0.2	211	24.0	1	0.1	2	0.2	1	0.2	0	0.0
Methotrexate-All Routes	3542	36.3	2100	83.4	17	0.7	163	15.7	815	91.0	1	0.1	7	0.8	29	6.5	410	50.3
Methotrexate-IM	495	5.1	464	19.1	0	0.0	0	0.0	30	3.4	0	0.0	1	0.1	0	0.0	0	0.0
Methotrexate-IT/Ommaya	2641	27.4	1889	78.0	5	0.2	6	0.6	714	81.6	1	0.1	3	0.3	17	3.8	6	0.7
Methotrexate-IV	2472	25.7	1299	53.6	10	0.4	156	15.1	593	67.8	0	0.0	5	0.6	12	2.7	397	49.2
Methotrexate-PO	920	9.6	807	33.3	4	0.2	1	0.1	108	12.3	0	0.0	0	0.0	0	0.0	0	0.0
Mitoxantrone	118	1.2	89	3.7	0	0.0	24	2.3	4	0.5	1	0.1	0	0.0	0	0.0	0	0.0
Prednisone	3310	34.0	1742	69.9	59	2.6	774	72.8	707	79.3	7	0.8	8	0.9	4	0.9	9	1.1
Procarbazine	871	9.0	0	0.0	162	7.0	703	67.7	6	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Taxotere	17	0.2	0	0.0	2	0.1	3	0.3	0	0.0	0	0.0	3	0.3	1	0.2	8	1.0
Temozolomide	41	0.4	0	0.0	35	1.5	0	0.0	1	0.1	0	0.0	4	0.5	0	0.0	1	0.1
Teniposide (VM-26)	333	3.5	269	11.1	0	0.0	1	0.1	31	3.5	0	0.0	29	3.4	0	0.0	3	0.4
Thioguanine (6-TG)	1219	12.6	1028	42.0	58	2.5	0	0.0	132	15.1	0	0.0	0	0.0	0	0.0	1	0.1
Thiotepa-All Routes	128	1.3	18	0.7	42	1.8	4	0.4	24	2.7	6	0.7	21	2.4	4	0.9	9	1.1
Thiotepa-IT	4	0.0	1	0.0	2	0.1	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Thiotepa-IV/IM	122	1.3	17	0.7	39	1.7	4	0.4	23	2.6	6	0.7	21	2.4	4	0.9	8	1.0
Topotecan	154	1.6	11	0.5	37	1.6	3	0.3	1	0.1	6	0.7	55	6.3	17	3.8	24	3.0
Vinblastine	883	9.1	6	0.2	17	0.7	849	80.5	8	0.9	1	0.1	0	0.0	2	0.5	0	0.0
Vincristine	6471	65.8	1993	79.6	915	39.3	780	74.4	875	98.3	889	97.3	165	19.0	456	99.1	398	48.8
Vinorelbine	14	0.1	0	0.0	2	0.1	7	0.7	0	0.0	1	0.1	2	0.2	1	0.2	1	0.1
ATG	33	0.3	29	1.2	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	1	0.2	1	0.1
Alemtuzumab (Campath)	2	0.0	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Cyclosporine (CSA)	125	1.3	105	4.3	4	0.2	1	0.1	9	1.0	0	0.0	3	0.3	0	0.0	3	0.4
Mycophenolate (CellCept)	1	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Rituximab (Rituxan)	17	0.2	3	0.1	0	0.0	2	0.2	10	1.1	0	0.0	0	0.0	0	0.0	2	0.2
Sirolemus	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Tacrolimus	16	0.2	14	0.6	0	0.0	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0
Erythropoietin (EPO)	19	0.2	5	0.2	0	0.0	0	0.0	1	0.1	1	0.1	3	0.3	5	1.1	4	0.5
GCSF	1366	14.1	275	11.3	166	7.2	92	8.9	219	24.9	49	5.6	168	19.0	150	33.0	247	29.6
GMCSF	64	0.7	18	0.7	5	0.2	6	0.6	5	0.6	1	0.1	17	2.0	3	0.7	9	1.1
Interferon	26	0.3	18	0.7	2	0.1	1	0.1	2	0.2	0	0.0	2	0.2	0	0.0	1	0.1
Interleukin-2	33	0.3	19	0.8	0	0.0	3	0.3	0	0.0	0	0.0	7	0.8	0	0.0	4	0.5
Mesna	1308	13.5	134	5.5	206	8.9	46	4.4	140	16.0	50	5.7	133	15.2	194	42.5	405	48.4
Retinoic Acid	153	1.6	45	1.9	7	0.3	1	0.1	1	0.1	0	0.0	98	11.2	0	0.0	1	0.1
Zinecard (Dexrazoxane)	41	0.4	12	0.5	0	0.0	10	1.0	6	0.7	0	0.0	1	0.1	2	0.5	10	1.2

**Treatment Exposure During First 5 Years after Primary Cancer by Cancer Diagnosis:  
Original Cohort Participants with Complete Abstraction of Medical Records (N=12596)<sup>1</sup>**

Agent		Participants		Leukemia		CNS		HD		NHL		Kidney (Wilms)		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Total		12596	100.0	4278	100.0	1660	100.0	1675	100.0	922	100.0	1086	100.0	835	100.0	1096	100.0	1044	100.0
Any radiation	Yes	8550	68.1	2958	69.4	1191	72.1	1577	94.1	633	68.7	702	64.7	411	49.3	695	63.6	383	36.8
	No	4013	31.9	1303	30.6	462	27.9	98	5.9	288	31.3	383	35.3	422	50.7	398	36.4	659	63.2
	Pending	33	.	17	.	7	.	0	.	1	.	1	.	2	.	3	.	2	.
Max Brain RT dose	None	4128	33.9	1370	33.2	480	30.6	107	6.6	290	32.3	386	36.6	424	51.8	403	38.1	668	65.4
	1-19.9 Gy <sup>2</sup>	5109	42.0	1328	32.2	45	2.9	1493	92.0	413	46.0	669	63.4	362	44.2	466	44.0	333	32.6
	20-29.9 Gy	1434	11.8	1264	30.7	5	0.3	7	0.4	141	15.7	0	0.0	8	1.0	8	0.8	1	0.1
	30-49.9 Gy	489	4.0	153	3.7	185	11.8	15	0.9	43	4.8	1	0.1	13	1.6	69	6.5	10	1.0
	>=50 Gy	1008	8.3	8	0.2	854	54.4	1	0.1	11	1.2	0	0.0	12	1.5	113	10.7	9	0.9
	Pending	428	.	155	.	91	.	52	.	24	.	30	.	16	.	37	.	23	.
Max dose to chest <sup>1</sup>	None	4128	34.0	1370	33.2	480	30.5	107	6.6	290	32.3	386	36.6	424	51.8	403	38.2	668	65.7
	1-19.9 Gy <sup>2</sup>	5481	45.1	2540	61.5	672	42.7	163	10.1	410	45.7	576	54.5	288	35.2	561	53.1	271	26.7
	20-29.9 Gy	780	6.4	204	4.9	98	6.2	249	15.4	89	9.9	68	6.4	60	7.3	5	0.5	7	0.7
	>=30 Gy	1769	14.6	14	0.3	322	20.5	1096	67.9	108	12.0	26	2.5	46	5.6	87	8.2	70	6.9
	Pending	438	.	150	.	88	.	60	.	25	.	30	.	17	.	40	.	28	.
Neck	Yes	2967	24.3	559	13.5	443	28.1	1441	88.6	275	30.6	17	1.6	93	11.3	120	11.3	19	1.9
	No	9226	75.7	3577	86.5	1132	71.9	185	11.4	624	69.4	1039	98.4	727	88.7	939	88.7	1003	98.1
	Pending	403	.	142	.	85	.	49	.	23	.	30	.	15	.	37	.	22	.
Spine	Yes	1054	8.6	542	13.1	419	26.6	4	0.2	48	5.3	0	0.0	26	3.2	10	0.9	5	0.5
	No	11135	91.4	3594	86.9	1156	73.4	1620	99.8	850	94.7	1056	100.0	793	96.8	1049	99.1	1017	99.5
	Pending	407	.	142	.	85	.	51	.	24	.	30	.	16	.	37	.	22	.
Abdomen	Yes	3222	26.4	563	13.6	436	27.7	980	60.3	201	22.3	664	62.8	231	28.2	96	9.1	51	5.0
	No	8972	73.6	3573	86.4	1139	72.3	645	39.7	699	77.7	394	37.2	588	71.8	963	90.9	971	95.0
	Pending	402	.	142	.	85	.	50	.	22	.	28	.	16	.	37	.	22	.
Pelvis	Yes	2629	21.6	558	13.5	424	26.9	640	39.4	197	21.9	383	36.2	150	18.3	186	17.6	91	8.9
	No	9565	78.4	3578	86.5	1151	73.1	985	60.6	703	78.1	675	63.8	669	81.7	873	82.4	931	91.1
	Pending	402	.	142	.	85	.	50	.	22	.	28	.	16	.	37	.	22	.
Limb	Yes	570	4.7	174	4.2	1	0.1	18	1.1	59	6.6	3	0.3	20	2.4	123	11.6	172	16.8
	No	11617	95.3	3960	95.8	1574	99.9	1606	98.9	839	93.4	1053	99.7	799	97.6	936	88.4	850	83.2
	Pending	409	.	144	.	85	.	51	.	24	.	30	.	16	.	37	.	22	.
TBI	Yes	196	1.6	157	3.8	0	0.0	3	0.2	14	1.6	0	0.0	16	2.0	3	0.3	3	0.3
	No	11990	98.4	3976	96.2	1575	100.0	1621	99.8	884	98.4	1056	100.0	803	98.0	1056	99.7	1019	99.7

	Pending	410	.	145	.	85	.	51	.	24	.	30	.	16	.	37	.	22	.
Any chemotherapy	Yes	10140	80.6	4276	100.0	500	30.2	1122	67.2	872	94.7	1069	98.4	495	59.4	867	79.3	939	89.9
	No	2438	19.4	2	0.0	1153	69.8	548	32.8	49	5.3	17	1.6	338	40.6	226	20.7	105	10.1
	Pending	18	.	0	.	7	.	5	.	1	.	0	.	2	.	3	.	0	.
Alkylating agents (CED, mg/m2) <sup>1</sup>	None	6022	52.7	1991	50.9	1284	81.9	631	45.8	113	13.8	986	92.1	346	45.6	355	36.2	316	33.7
	>0 - <4000	1324	11.6	890	22.8	34	2.2	37	2.7	145	17.7	20	1.9	57	7.5	53	5.4	88	9.4
	>=4000 - <8000	1216	10.6	407	10.4	36	2.3	140	10.2	161	19.7	38	3.5	118	15.5	86	8.8	230	24.5
	>=8000 - <12000	1082	9.5	293	7.5	83	5.3	253	18.4	169	20.6	8	0.7	74	9.7	120	12.2	82	8.7
	>=12000 - <16000	760	6.7	113	2.9	82	5.2	201	14.6	108	13.2	4	0.4	58	7.6	106	10.8	88	9.4
	>=16000 - <20000	456	4.0	91	2.3	22	1.4	52	3.8	68	8.3	5	0.5	38	5.0	113	11.5	67	7.1
	>=20000	564	4.9	124	3.2	26	1.7	64	4.6	55	6.7	10	0.9	68	9.0	149	15.2	68	7.2
	Unknown	1172	.	369	.	93	.	297	.	103	.	15	.	76	.	114	.	105	.
Anthracycline dose (mg/m2) <sup>1</sup>	None	7596	63.0	2215	54.7	1643	99.6	1281	79.0	400	46.6	638	60.6	605	74.1	624	59.3	190	20.1
	>0 - <100	480	4.0	352	8.7	0	0.0	23	1.4	18	2.1	16	1.5	29	3.5	23	2.2	19	2.0
	>=100 - <250	1349	11.2	608	15.0	4	0.2	160	9.9	148	17.2	165	15.7	105	12.9	82	7.8	77	8.2
	>=250 - <400	1600	13.3	490	12.1	2	0.1	142	8.8	193	22.5	215	20.4	50	6.1	178	16.9	330	35.0
	>=400	1024	8.5	388	9.6	1	0.1	16	1.0	100	11.6	18	1.7	28	3.4	146	13.9	327	34.7
	Unknown	547	.	225	.	10	.	53	.	63	.	34	.	18	.	43	.	101	.

<sup>1</sup> Unknown doses are excluded from percentage calculations, <sup>2</sup> Includes scatter doses of radiation

**Exposure to Specific Treatment Agents During First 5 Years after Primary Cancer by Cancer Diagnosis:  
Original Cohort Participants with Complete Abstraction of Medical Records (N=12596)**

Agent	Participants		Leukemia		CNS		HD		NHL		Kidney (Wilms)		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
5-Azacytidine	183	1.5	181	4.2	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Bleomycin	709	5.6	4	0.1	7	0.4	337	20.2	53	5.8	2	0.2	2	0.2	46	4.2	258	24.7
Busulfan	27	0.2	24	0.6	0	0.0	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Carboplatin	33	0.3	0	0.0	13	0.8	1	0.1	0	0.0	0	0.0	8	1.0	2	0.2	9	0.9
Carmustine (BCNU)	475	3.8	186	4.3	33	2.0	36	2.2	185	20.1	0	0.0	2	0.2	13	1.2	20	1.9
Chlorambucil	62	0.5	0	0.0	0	0.0	41	2.5	4	0.4	0	0.0	0	0.0	10	0.9	7	0.7
Cisplatin	656	5.2	6	0.1	136	8.2	13	0.8	9	1.0	18	1.7	107	12.8	99	9.1	268	25.7
Cyclophosphamide-All Routes	5521	43.9	2258	52.8	100	6.0	357	21.4	796	86.4	88	8.1	479	57.5	727	66.5	716	68.6
Cyclophosphamide-IV/IM	4881	38.8	1954	45.7	89	5.4	347	20.8	773	83.9	84	7.7	358	43.0	612	56.0	664	63.6
Cyclophosphamide-PO	988	7.9	395	9.2	13	0.8	14	0.8	43	4.7	5	0.5	225	27.0	191	17.5	102	9.8
Cytarabine	2971	23.6	2367	55.3	88	5.3	26	1.6	410	44.5	1	0.1	17	2.0	52	4.8	10	1.0
Dacarbazine (DTIC)	592	4.7	4	0.1	34	2.1	260	15.6	3	0.3	4	0.4	164	19.7	86	7.9	37	3.5
Dactinomycin	2508	19.9	54	1.3	39	2.4	3	0.2	15	1.6	1063	97.9	12	1.4	783	71.6	539	51.6
Daunorubicin	1583	12.6	1312	30.7	1	0.1	0	0.0	260	28.2	0	0.0	5	0.6	3	0.3	2	0.2
Dexamethasone	988	7.9	583	13.6	115	7.0	53	3.2	73	7.9	6	0.6	20	2.4	42	3.8	96	9.2
Doxorubicin	3882	30.9	1211	28.3	8	0.5	384	23.0	291	31.6	448	41.3	223	26.8	465	42.5	852	81.6
Epirubicin	3	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	1	0.1
Etoposide (VP-16)-All Routes	640	5.1	398	9.3	33	2.0	26	1.6	37	4.0	25	2.3	18	2.2	64	5.9	39	3.7
Etoposide (VP-16)-IV/IM	629	5.0	398	9.3	29	1.8	22	1.3	36	3.9	25	2.3	17	2.0	63	5.8	39	3.7
Etoposide (VP-16)-PO	16	0.1	4	0.1	5	0.3	5	0.3	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0
Fludarabine phosphate	2	0.0	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Fluorouracil (5-FU)	66	0.5	4	0.1	13	0.8	2	0.1	2	0.2	5	0.5	8	1.0	9	0.8	23	2.2
Hydroxyurea	511	4.1	191	4.5	117	7.1	1	0.1	187	20.3	0	0.0	11	1.3	3	0.3	1	0.1
Idarubicin	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ifosfamide	97	0.8	6	0.1	4	0.2	1	0.1	5	0.5	15	1.4	4	0.5	27	2.5	35	3.4
L-Asparaginase	3938	31.3	3638	85.0	3	0.2	0	0.0	297	32.2	0	0.0	0	0.0	0	0.0	0	0.0
Lomustine (CCNU)	446	3.5	14	0.3	256	15.5	140	8.4	31	3.4	0	0.0	1	0.1	1	0.1	3	0.3
Mechlorethamine (N. Mustard)	752	6.0	6	0.1	42	2.5	624	37.4	21	2.3	1	0.1	35	4.2	15	1.4	8	0.8
Melphalan-All Routes	121	1.0	4	0.1	2	0.1	32	1.9	1	0.1	0	0.0	31	3.7	6	0.5	45	4.3
Melphalan-IV/IM	83	0.7	3	0.1	0	0.0	3	0.2	0	0.0	0	0.0	27	3.2	6	0.5	44	4.2
Melphalan-PO	38	0.3	1	0.0	1	0.1	29	1.7	1	0.1	0	0.0	5	0.6	0	0.0	1	0.1
Mercaptopurine (6-MP)	3966	31.5	3682	86.1	6	0.4	2	0.1	273	29.6	0	0.0	0	0.0	3	0.3	0	0.0

Methotrexate-All Routes	5637	44.8	4115	96.2	50	3.0	23	1.4	790	85.8	0	0.0	10	1.2	108	9.9	541	51.8
Methotrexate-IM	473	3.8	435	10.2	0	0.0	0	0.0	32	3.5	0	0.0	0	0.0	1	0.1	5	0.5
Methotrexate-IT/Ommaya	4583	36.4	3805	88.9	26	1.6	1	0.1	692	75.1	0	0.0	5	0.6	46	4.2	8	0.8
Methotrexate-IV	2627	20.9	1629	38.1	17	1.0	14	0.8	380	41.3	0	0.0	4	0.5	58	5.3	525	50.3
Methotrexate-PO	3500	27.8	3094	72.3	9	0.5	8	0.5	378	41.0	0	0.0	0	0.0	4	0.4	7	0.7
Mitoxantrone	10	0.1	6	0.1	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	2	0.2	1	0.1
Prednisone	5839	46.4	3976	92.9	156	9.4	843	50.5	804	87.3	8	0.7	14	1.7	21	1.9	17	1.6
Procarbazine	1230	9.8	2	0.0	201	12.2	1004	60.1	16	1.7	0	0.0	6	0.7	1	0.1	0	0.0
Taxol	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Teniposide (VM-26)	587	4.7	432	10.1	10	0.6	4	0.2	44	4.8	3	0.3	84	10.1	7	0.6	3	0.3
Thioguanine (6-TG)	1170	9.3	913	21.3	26	1.6	2	0.1	228	24.8	1	0.1	0	0.0	0	0.0	0	0.0
Thiotepa-All Routes	39	0.3	4	0.1	2	0.1	29	1.7	2	0.2	0	0.0	1	0.1	0	0.0	1	0.1
Thiotepa-IT	2	0.0	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Thiotepa-IV/IM	34	0.3	1	0.0	2	0.1	29	1.7	1	0.1	0	0.0	0	0.0	0	0.0	1	0.1
Topotecan	4	0.0	2	0.0	1	0.1	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0
Vinblastine	562	4.5	24	0.6	3	0.2	485	29.0	23	2.5	9	0.8	7	0.8	6	0.5	5	0.5
Vincristine	8969	71.3	4085	95.5	356	21.5	907	54.3	834	90.6	993	91.4	307	36.9	805	73.7	682	65.3
Vinorelbine	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cyclosporine (CSA)	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
GCSF	7	0.1	4	0.1	1	0.1	0	0.0	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0
GMCSF	3	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	2	0.2
Interferon	12	0.1	9	0.2	0	0.0	0	0.0	0	0.0	1	0.1	1	0.1	0	0.0	1	0.1
Interleukin-2	3	0.0	2	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Mesna	20	0.2	6	0.1	3	0.2	0	0.0	0	0.0	3	0.3	1	0.1	3	0.3	4	0.4
Retinoic Acid	6	0.0	3	0.1	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0

**Exposure to Specific Treatment Agents During First 5 Years after Primary Cancer by Cancer Diagnosis:  
Overall Cohort Participants with Complete Abstraction of Medical Records (N=22343)<sup>1</sup>**

Agent		Participants		Leukemia		CNS		HD		NHL		Kidney (Wilms)		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Total		22343	100.0	6717	100.0	4029	100.0	2727	100.0	1802	100.0	1965	100.0	1708	100.0	1541	100.0	1854	100.0
Any radiation	Yes	12725	57.3	3749	56.1	2401	60.1	2382	87.8	797	44.4	1123	57.4	651	38.3	1022	66.5	600	32.5
	No	9500	42.7	2939	43.9	1591	39.9	332	12.2	998	55.6	835	42.6	1047	61.7	514	33.5	1244	67.5
	Pending	118	.	29	.	37	.	13	.	7	.	7	.	10	.	5	.	10	.
Max dose to brain <sup>1</sup>	None	9892	45.8	3057	47.2	1645	43.6	407	15.3	1010	57.5	881	45.7	1073	64.2	549	36.7	1270	69.7
	1-19.9 Gy <sup>2</sup>	7466	34.6	1870	28.8	89	2.4	2231	83.8	534	30.4	1043	54.1	539	32.3	649	43.4	511	28.0
	20-29.9 Gy	1591	7.4	1376	21.2	9	0.2	8	0.3	149	8.5	1	0.1	26	1.6	19	1.3	3	0.2
	30-49.9 Gy	640	3.0	172	2.7	244	6.5	15	0.6	52	3.0	2	0.1	18	1.1	115	7.7	22	1.2
	>=50 Gy	2003	9.3	8	0.1	1786	47.3	1	0.0	12	0.7	0	0.0	15	0.9	165	11.0	16	0.9
	Pending	751	.	234	.	256	.	65	.	45	.	38	.	37	.	44	.	32	.
Max dose to chest <sup>1</sup>	None	9968	46.0	3070	47.2	1759	45.0	370	14.1	1011	57.6	872	45.5	1072	64.2	548	36.7	1266	69.8
	1-19.9 Gy <sup>2</sup>	7836	36.2	3208	49.3	1201	30.8	263	10.1	532	30.3	931	48.6	453	27.1	833	55.8	415	22.9
	20-29.9 Gy	1435	6.6	210	3.2	273	7.0	672	25.7	93	5.3	81	4.2	90	5.4	6	0.4	10	0.6
	>=30 Gy	2435	11.2	15	0.2	672	17.2	1311	50.1	120	6.8	33	1.7	55	3.3	107	7.2	122	6.7
	Pending	669	.	214	.	124	.	111	.	46	.	48	.	38	.	47	.	41	.
Neck	Yes	4788	21.9	888	13.5	982	25.1	2164	81.2	339	19.1	28	1.5	177	10.5	164	10.9	46	2.5
	No	17059	78.1	5674	86.5	2929	74.9	501	18.8	1433	80.9	1899	98.5	1508	89.5	1338	89.1	1777	97.5
	Pending	496	.	155	.	118	.	62	.	30	.	38	.	23	.	39	.	31	.
Spine	Yes	2122	9.7	876	13.3	1004	25.7	12	0.5	90	5.1	0	0.0	107	6.4	17	1.1	16	0.9
	No	19721	90.3	5686	86.7	2907	74.3	2651	99.5	1681	94.9	1927	100.0	1577	93.6	1485	98.9	1807	99.1
	Pending	500	.	155	.	118	.	64	.	31	.	38	.	24	.	39	.	31	.
Abdomen	Yes	5129	23.5	890	13.6	981	25.1	1288	48.3	255	14.4	1043	54.1	427	25.4	149	9.9	96	5.3
	No	16718	76.5	5672	86.4	2930	74.9	1376	51.7	1518	85.6	886	45.9	1257	74.6	1353	90.1	1726	94.7
	Pending	496	.	155	.	118	.	63	.	29	.	36	.	24	.	39	.	32	.
Pelvis	Yes	4254	19.5	882	13.4	958	24.5	816	30.6	252	14.2	621	32.2	270	16.0	288	19.2	167	9.2
	No	17594	80.5	5680	86.6	2953	75.5	1848	69.4	1521	85.8	1308	67.8	1414	84.0	1214	80.8	1656	90.8
	Pending	495	.	155	.	118	.	63	.	29	.	36	.	24	.	39	.	31	.
Limb	Yes	1123	5.1	425	6.5	5	0.1	77	2.9	104	5.9	5	0.3	109	6.5	152	10.1	246	13.5
	No	20718	94.9	6135	93.5	3906	99.9	2586	97.1	1667	94.1	1922	99.7	1575	93.5	1350	89.9	1577	86.5
	Pending	502	.	157	.	118	.	64	.	31	.	38	.	24	.	39	.	31	.
TBI	Yes	571	2.6	406	6.2	2	0.1	7	0.3	48	2.7	0	0.0	90	5.3	4	0.3	14	0.8
	No	21269	97.4	6153	93.8	3909	99.9	2656	99.7	1723	97.3	1927	100.0	1594	94.7	1498	99.7	1809	99.2

	Pending	503	.	158	.	118	.	64	.	31	.	38	.	24	.	39	.	31	.
Any chemotherapy	Yes	18106	81.5	6692	99.9	1587	40.1	2081	76.9	1746	97.2	1929	98.2	1041	61.3	1309	85.2	1721	93.0
	No	4103	18.5	9	0.1	2370	59.9	625	23.1	50	2.8	35	1.8	657	38.7	227	14.8	130	7.0
	Pending	134	.	16	.	72	.	21	.	6	.	1	.	10	.	5	.	3	.
Alkylating agents (CED, mg/m2) <sup>1</sup>	None	10095	49.1	2904	46.8	2797	73.9	908	38.6	171	10.4	1747	90.0	677	43.6	445	31.8	446	26.3
	>0 - <4000	2595	12.6	1589	25.6	107	2.8	114	4.8	355	21.5	38	2.0	165	10.6	68	4.9	159	9.4
	>=4000 - <8000	2682	13.0	691	11.1	147	3.9	571	24.3	491	29.8	61	3.1	300	19.3	100	7.1	321	18.9
	>=8000 - <12000	2133	10.4	604	9.7	307	8.1	370	15.7	330	20.0	37	1.9	119	7.7	158	11.3	208	12.3
	>=12000 - <16000	1224	5.9	176	2.8	221	5.8	242	10.3	136	8.2	29	1.5	111	7.2	145	10.4	164	9.7
	>=16000 - <20000	701	3.4	107	1.7	101	2.7	65	2.8	89	5.4	7	0.4	69	4.4	142	10.2	121	7.1
	>=20000	1150	5.6	137	2.2	105	2.8	81	3.4	78	4.7	22	1.1	110	7.1	341	24.4	276	16.3
	Unknown	1763	.	509	.	244	.	376	.	152	.	24	.	157	.	142	.	159	.
Anthracycline dose (mg/m2) <sup>1</sup>	None	11588	54.1	2555	40.0	3922	99.3	1430	54.5	503	29.5	1060	55.3	991	60.3	902	60.8	225	13.1
	>0 - <100	1406	6.6	951	14.9	0	0.0	79	3.0	101	5.9	78	4.1	123	7.5	34	2.3	40	2.3
	>=100 - <250	4045	18.9	1516	23.7	11	0.3	806	30.7	581	34.1	443	23.1	392	23.9	119	8.0	177	10.3
	>=250 - <400	2949	13.8	892	14.0	14	0.4	288	11.0	384	22.5	312	16.3	100	6.1	251	16.9	708	41.3
	>=400	1439	6.7	477	7.5	3	0.1	23	0.9	134	7.9	23	1.2	37	2.3	178	12.0	564	32.9
	Unknown	916	.	326	.	79	.	101	.	99	.	49	.	65	.	57	.	140	.

<sup>1</sup> Unknown doses are excluded from percentage calculations, <sup>2</sup> Includes scatter doses of radiation

**Exposure to Specific Treatment Agents During First 5 Years after Primary Cancer by Cancer Diagnosis:  
Overall Cohort Participants with Complete Abstraction of Medical Records (N=22343)**

Agent	Participants		Leukemia		CNS		HD		NHL		Kidney (Wilms)		Neuroblastoma		Soft tissue sarcoma		Bone cancer	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
5-Azacytidine	292	1.3	288	4.3	2	0.1	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
ARA-G	4	0.0	2	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Bleomycin	1504	6.8	4	0.1	10	0.3	1020	37.7	71	4.0	2	0.1	2	0.1	53	3.5	342	18.5
Busulfan	207	0.9	183	2.7	4	0.1	9	0.3	1	0.1	3	0.2	0	0.0	2	0.1	5	0.3
Carboplatin	814	3.7	5	0.1	377	9.5	17	0.6	38	2.1	52	2.6	226	13.2	20	1.3	79	4.3
Carmustine (BCNU)	586	2.6	189	2.8	62	1.6	71	2.6	226	12.6	0	0.0	4	0.2	13	0.8	21	1.1
Chlorambucil	67	0.3	0	0.0	0	0.0	46	1.7	4	0.2	0	0.0	0	0.0	10	0.7	7	0.4
Cisplatin	2057	9.3	8	0.1	684	17.3	44	1.6	51	2.8	18	0.9	488	28.6	133	8.7	631	34.0
Cyclophosphamide-All Routes	10244	45.8	3800	56.3	536	13.5	835	30.7	1619	89.5	180	9.2	1031	59.6	1067	68.8	1176	63.0
Cyclophosphamide-IV/IM	9350	42.1	3428	51.2	509	12.9	808	29.9	1582	88.1	173	8.8	821	48.4	937	61.0	1092	59.0
Cyclophosphamide-PO	1161	5.2	407	6.1	21	0.5	14	0.5	44	2.4	6	0.3	354	20.8	191	12.4	124	6.7
Cytarabine	6169	27.5	4725	68.8	155	3.9	96	3.5	1076	59.2	4	0.2	24	1.4	69	4.5	20	1.1
Dacarbazine (DTIC)	974	4.4	4	0.1	57	1.4	568	21.0	3	0.2	4	0.2	199	11.7	89	5.8	50	2.7
Dactinomycin	4037	18.1	66	1.0	88	2.2	7	0.3	20	1.1	1897	95.3	18	1.1	1171	75.8	770	41.5
Daunorubicin	3519	15.8	3002	44.6	2	0.1	6	0.2	488	27.1	2	0.1	9	0.5	5	0.3	5	0.3
Dexamethasone	2930	13.1	1765	26.2	315	7.9	163	6.0	251	13.9	27	1.4	71	4.2	88	5.7	250	13.4
Doxorubicin	8086	36.3	1972	29.4	29	0.7	1281	47.1	922	51.2	909	46.2	711	41.6	630	41.0	1632	87.8
Epirubicin	4	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	1	0.1	1	0.1
Etoposide (VP-16)-All Routes	3604	16.1	1469	21.8	398	10.0	214	7.9	316	17.6	131	6.7	465	27.0	231	15.0	380	20.3
Etoposide (VP-16)-IV/IM	3440	15.5	1426	21.3	358	9.0	201	7.4	311	17.3	126	6.4	435	25.6	223	14.5	360	19.4
Etoposide (VP-16)-PO	85	0.4	25	0.4	35	0.9	7	0.3	2	0.1	0	0.0	7	0.4	2	0.1	7	0.4
Fludarabine phosphate	69	0.3	53	0.8	2	0.1	3	0.1	5	0.3	0	0.0	2	0.1	1	0.1	3	0.2
Fluorouracil (5-FU)	73	0.3	6	0.1	14	0.4	3	0.1	3	0.2	5	0.3	9	0.5	10	0.7	23	1.2
Gemcitabine	17	0.1	0	0.0	0	0.0	4	0.1	0	0.0	1	0.1	1	0.1	2	0.1	9	0.5
Gemtuzimab (Mylotarg)	6	0.0	3	0.0	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	0	0.0	1	0.1
Gleevec	15	0.1	8	0.1	1	0.0	0	0.0	0	0.0	0	0.0	1	0.1	3	0.2	2	0.1
Hydroxyurea	689	3.1	268	4.0	180	4.5	1	0.0	220	12.2	1	0.1	15	0.9	3	0.2	1	0.1
Idarubicin	181	0.8	173	2.6	4	0.1	1	0.0	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Ifosfamide	1204	5.4	39	0.6	65	1.6	28	1.0	79	4.4	58	3.0	115	6.8	247	16.0	573	30.6
Irinotecan	43	0.2	3	0.0	11	0.3	0	0.0	0	0.0	2	0.1	16	0.9	6	0.4	5	0.3
L-Asparaginase	6099	27.4	5503	81.1	5	0.1	12	0.4	572	31.8	0	0.0	3	0.2	1	0.1	3	0.2
Lomustine (CCNU)	828	3.7	14	0.2	620	15.7	157	5.8	32	1.8	0	0.0	1	0.1	1	0.1	3	0.2
Mechlorethamine (N. Mustard)	1092	4.9	7	0.1	59	1.5	933	34.5	24	1.3	1	0.1	45	2.7	15	1.0	8	0.4

Melphalan-All Routes	279	1.3	14	0.2	9	0.2	35	1.3	3	0.2	4	0.2	125	7.4	23	1.5	66	3.6
Melphalan-IV/IM	234	1.1	12	0.2	6	0.2	6	0.2	1	0.1	4	0.2	117	6.9	23	1.5	65	3.5
Melphalan-PO	40	0.2	1	0.0	1	0.0	29	1.1	2	0.1	0	0.0	6	0.4	0	0.0	1	0.1
Mercaptopurine (6-MP)	5850	26.3	5345	78.9	10	0.3	4	0.1	484	26.9	1	0.1	2	0.1	4	0.3	0	0.0
Methotrexate-All Routes	9179	41.1	6215	91.5	67	1.7	186	6.9	1605	88.3	1	0.1	17	1.0	137	8.9	951	51.2
Methotrexate-IM	968	4.4	899	13.4	0	0.0	0	0.0	62	3.5	0	0.0	1	0.1	1	0.1	5	0.3
Methotrexate-IT/Ommaya	7224	32.5	5694	85.0	31	0.8	7	0.3	1406	78.3	1	0.1	8	0.5	63	4.1	14	0.8
Methotrexate-IV	5099	23.0	2928	43.7	27	0.7	170	6.3	973	54.2	0	0.0	9	0.5	70	4.6	922	49.8
Methotrexate-PO	4420	19.9	3901	58.2	13	0.3	9	0.3	486	27.1	0	0.0	0	0.0	4	0.3	7	0.4
Mitoxantrone	128	0.6	95	1.4	0	0.0	24	0.9	4	0.2	1	0.1	1	0.1	2	0.1	1	0.1
Prednisone	9149	41.0	5718	84.5	215	5.4	1617	59.2	1511	83.3	15	0.8	22	1.3	25	1.6	26	1.4
Procarbazine	2101	9.5	2	0.0	363	9.2	1707	63.0	22	1.2	0	0.0	6	0.4	1	0.1	0	0.0
Taxol	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Taxotere	17	0.1	0	0.0	2	0.1	3	0.1	0	0.0	0	0.0	3	0.2	1	0.1	8	0.4
Temozolomide	41	0.2	0	0.0	35	0.9	0	0.0	1	0.1	0	0.0	4	0.2	0	0.0	1	0.1
Teniposide (VM-26)	920	4.1	701	10.5	10	0.3	5	0.2	75	4.2	3	0.2	113	6.7	7	0.5	6	0.3
Thioguanine (6-TG)	2389	10.7	1941	28.9	84	2.1	2	0.1	360	20.0	1	0.1	0	0.0	0	0.0	1	0.1
Thiotepa-All Routes	167	0.8	22	0.3	44	1.1	33	1.2	26	1.4	6	0.3	22	1.3	4	0.3	10	0.5
Thiotepa-IT	6	0.0	2	0.0	2	0.1	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Thiotepa-IV/IM	156	0.7	18	0.3	41	1.0	33	1.2	24	1.3	6	0.3	21	1.2	4	0.3	9	0.5
Topotecan	158	0.7	13	0.2	38	1.0	3	0.1	1	0.1	6	0.3	56	3.3	17	1.1	24	1.3
Vinblastine	1445	6.5	30	0.4	20	0.5	1334	49.0	31	1.7	10	0.5	7	0.4	8	0.5	5	0.3
Vincristine	15440	68.9	6078	89.6	1271	31.9	1687	62.0	1709	94.4	1882	94.1	472	27.7	1261	81.2	1080	58.1
Vinorelbine	15	0.1	0	0.0	2	0.1	8	0.3	0	0.0	1	0.1	2	0.1	1	0.1	1	0.1
ATG	33	0.1	29	0.4	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	1	0.1	1	0.1
Alemtuzumab (Campath)	2	0.0	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Cyclosporine (CSA)	126	0.6	106	1.6	4	0.1	1	0.0	9	0.5	0	0.0	3	0.2	0	0.0	3	0.2
Mycophenolate (CellCept)	1	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Rituximab (Rituxan)	17	0.1	3	0.0	0	0.0	2	0.1	10	0.6	0	0.0	0	0.0	0	0.0	2	0.1
Sirolimus	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Tacrolimus	16	0.1	14	0.2	0	0.0	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0
Erythropoietin (EPO)	19	0.1	5	0.1	0	0.0	0	0.0	1	0.1	1	0.1	3	0.2	5	0.3	4	0.2
GCSF	1373	6.2	279	4.2	167	4.2	92	3.4	219	12.2	50	2.5	169	9.8	150	9.7	247	13.2
GM-CSF	67	0.3	18	0.3	5	0.1	7	0.3	5	0.3	1	0.1	17	1.0	3	0.2	11	0.6
Interferon	38	0.2	27	0.4	2	0.1	1	0.0	2	0.1	1	0.1	3	0.2	0	0.0	2	0.1
Interleukin-2	36	0.2	21	0.3	0	0.0	3	0.1	0	0.0	1	0.1	7	0.4	0	0.0	4	0.2
Mesna	1328	6.0	140	2.1	209	5.3	46	1.7	140	7.8	53	2.7	134	7.9	197	12.7	409	21.7
Retinoic Acid	159	0.7	48	0.7	8	0.2	2	0.1	1	0.1	0	0.0	99	5.8	0	0.0	1	0.1
Zinecard (Dexrazoxane)	41	0.2	12	0.2	0	0.0	10	0.4	6	0.3	0	0.0	1	0.1	2	0.1	10	0.5